SGLT2 Inhibitor-induced Euglycemic Diabetic Ketoacidosis
Sodium-glucose co-transporter 2 inhibitors (SGLT2is) have emerged as a breakthrough therapy for the treatment of diabetes mellitus (DM) reducing key cardiovascular and kidney endpoints. These effects appear to be independent of their effects on blood pressure and glucose….
